| P50 | author | Kusheng Wu | Q57051477 |
| P2093 | author name string | Jingwen Zhang | |
| | Changyi Wang | |
| | Yanhong Huang | |
| | Shukai Zheng | |
| | Yuanfang He | |
| P2860 | cites work | Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). | Q42969835 |
| | Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. | Q43286764 |
| | Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group | Q43607761 |
| | Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma | Q43824354 |
| | Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen | Q44438549 |
| | Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group | Q44459245 |
| | Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study | Q44471667 |
| | Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results | Q44530802 |
| | Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. | Q44572714 |
| | Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy | Q44659411 |
| | Advanced breast cancer updates on anastrozole versus tamoxifen | Q44659418 |
| | Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial | Q44735204 |
| | The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane o | Q44754077 |
| | Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficac | Q44866175 |
| | Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial | Q44875574 |
| | Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability | Q45101561 |
| | Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer | Q45101563 |
| | Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer | Q46537570 |
| | Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer | Q46621611 |
| | Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control. | Q53874969 |
| | Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women | Q73135208 |
| | Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study | Q73190388 |
| | Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group | Q73190394 |
| | Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial | Q84475413 |
| | Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women | Q24239985 |
| | The Cochrane Collaboration's tool for assessing risk of bias in randomised trials | Q27860509 |
| | The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration | Q27860581 |
| | Measuring inconsistency in meta-analyses | Q27860655 |
| | Meta-analysis in clinical trials | Q27860779 |
| | Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 |
| | Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers | Q28081872 |
| | Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis | Q29619093 |
| | Combination of direct and indirect evidence in mixed treatment comparisons | Q29619499 |
| | The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials | Q29619501 |
| | ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† | Q30317067 |
| | Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial | Q33600403 |
| | Simultaneous comparison of multiple treatments: combining direct and indirect evidence. | Q34081552 |
| | A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer | Q34347274 |
| | First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen? | Q35622444 |
| | Letrozole in advanced breast cancer: the PO25 trial | Q36026424 |
| | Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer | Q36348100 |
| | Bayesian methods for evidence synthesis in cost-effectiveness analysis | Q36381197 |
| | Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials. | Q36614435 |
| | Evaluation of networks of randomized trials | Q36966424 |
| | Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group | Q37119390 |
| | A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered | Q37373846 |
| | Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial | Q37532641 |
| | Mixed treatment comparison analysis provides internally coherent treatment effect estimates based on overviews of reviews and can reveal inconsistency | Q37676533 |
| | Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer | Q37763872 |
| | Fulvestrant for advanced breast cancer: a meta-analysis | Q38114241 |
| | Use of tamoxifen for breast cancer: twenty-eight years later | Q40585050 |
| | Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study | Q42672762 |
| | Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. | Q42882393 |
| P433 | issue | 33 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e7846 | |
| P577 | publication date | 2017-08-01 | |
| P1433 | published in | Medicine | Q15716652 |
| P1476 | title | Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis | |
| P478 | volume | 96 | |